Sulfonylureas are one of the oldest antidiabetic agents present in clinical use since the 1950s. They lower glucose by augmenting insulin release through inhibition of adenosine triphosphate (ATP)–dependent potassium (KATP) channels in pancreatic beta cells.
Sulfonylureas can be a useful adjunct in diabetes management, especially when the cost of therapy is an issue.
United States Food and Drug Administration (FDA) approved glimepiride in 1995 for the treatment of T2DM as monotherapy as well as in combination with metformin or insulin.
- Drug class: Sulfonylureas
- Stimulates insulin release from pancreatic beta-cells and acts via extrapancreatic mechanisms.
- Effectively reduces fasting plasma glucose, postprandial glucose, and glycosylated hemoglobin levels.
- Associated with lower risk of hypoglycemia and less weight gain compared to other sulfonylureas.
- Glimepiride use may be safer in patients with cardiovascular disease because of its lack of detrimental effects on ischemic preconditioning.
Glimepiride 1 mg
- Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.